Clinical Trials on Syndromic Ichthyoses

Total 34283 results

Grupo Español de Síndromes Mielodisplásicos

Completed

Spanish Registry of Erythropoietic Stimulating Agents Study (SPRESAS)

Myelodysplastic Syndrome
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
Weill Medical College of Cornell University
CTI BioPharma

Completed

Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
University of Florida
Teva Pharmaceutical Industries, Ltd.

Withdrawn

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Shandong University

Unknown

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Myelodysplastic Syndromes

China
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Apogenix GmbH

Completed

APG101 in Myelodysplastic Syndrome (APG101 in MDS)

Myelodysplastic Syndrome

Germany
The Affiliated Hospital of the Chinese Academy...
The Second Artillery General Hospital

Completed

Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Ulsan University Hospital
Cooperative Study Group A for Hematology

Unknown

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome (VIOLET)

Myelodysplastic Syndrome

Korea, Republic of
Virginia Commonwealth University
Celgene Corporation

Completed

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
University of Pittsburgh

Completed

Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Singapore General Hospital
Johnson & Johnson

Terminated

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Myelodysplastic Syndrome

Singapore
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Completed

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007)

Myelodysplastic Syndromes

France
Samsung Medical Center

Completed

Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Kaplan Medical Center
Weizmann Institute of Science

Unknown

The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome

Myelodysplastic Syndrome

Israel
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Providence Hospital

Unknown

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Eisai Inc.

Completed

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Taiwan
Janssen Korea, Ltd., Korea

Completed

A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome
Telik

Completed

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
Texas Oncology Cancer Center
Genzyme, a Sanofi Company

Terminated

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Completed

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Myelodysplastic Syndrome

United States
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
European Organisation for Research and Treatment...

Completed

Infliximab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Belgium, Netherlands, Czech Republic, Italy, Germany
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Myelodysplastic Syndromes

Italy
Cooperative Study Group A for Hematology

Unknown

Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS) (CyFluATG)

Myelodysplastic Syndrome

Korea, Republic of
University of Utah
National Institutes of Health (NIH)

Completed

The Role of Erythropoietin in Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome
St. Bartholomew's Hospital

Unknown

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United Kingdom
PETHEMA Foundation

Completed

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Spain
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
Hadassah Medical Organization

Withdrawn

The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndrome

Israel
University of Rochester

Terminated

Non-invasive Ocular Surface Measurements Before and After Interventions

Healthy | Dry Eye Syndrome

United States
Minovia Therapeutics Ltd.

Recruiting

A Study to Evaluate the MNV-201 in Patients With Low Risk MDS

Myelodysplastic Syndromes

Israel
Wuhan Union Hospital, China

Not yet recruiting

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Myelodysplastic Syndromes
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit (JAKAHDI)

Hemophagocytic Syndromes
Otsuka Beijing Research Institute

Recruiting

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Bristol-Myers Squibb

Recruiting

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (MAXILUS)

Myelodysplastic Syndromes

Spain, United States, France, Italy, Belgium, Germany, Poland, Czechia, Puerto Rico
Peking Union Medical College Hospital

Not yet recruiting

Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Myelodysplastic Syndromes

China
University Hospital, Grenoble

Recruiting

Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study (MPO-MDS-Valid)

Myelodysplastic Syndromes

France
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

Myelodysplastic Syndromes

Japan
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
Novartis Pharmaceuticals

Terminated

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Myelodysplastic Syndromes

United States, Spain, Italy, Singapore, Korea, Republic of, Israel, Australia
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden
University Hospital, Grenoble

Active, not recruiting

Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes. (MPO-MDS-Develp)

Myelodysplastic Syndromes

France
Asan Medical Center

Active, not recruiting

CyFluATG in Lower Risk MDS

Myelodysplastic Syndromes

Korea, Republic of

Clinical Trials on Syndromic Ichthyoses

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations